7 news items
Establishment Labs Reports First Quarter 2024 Financial Results
ESTA
8 May 24
an investigational device exemption (IDE) from the FDA for Motiva Implants® and began a clinical trial to support
Establishment Labs Notes Presentation Of 4-Year Results From Motiva U.S. IDE Study At The Aesthetic Meeting 2024
ESTA
2 May 24
of the Study, Dr. Caroline Glicksman, who is also an Investigator in the Study, will present the results at The Aesthetic Meeting 2024 in Vancouver, BC
Establishment Labs Notes Presentation of 4-Year Results from Motiva U.S. IDE Study at The Aesthetic Meeting 2024
ESTA
2 May 24
augmentation subjects. The Medical Director of the Study, Dr. Caroline Glicksman, who is also an Investigator in the Study, will present the results
Establishment Labs Announces Appointment of Jeff Ehrhardt as General Manager of North America
ESTA
1 May 24
clinical investigation pursuant to U.S. FDA regulations for investigational medical devices
Establishment Labs to Announce First Quarter 2024 Financial Results on May 8
ESTA
24 Apr 24
and FDA 21 CFR 820 under the MDSAP program. In 2018, the Company received an investigational device exemption (IDE) from the FDA for Motiva Implants®
ryzx3m4bio11hlm2o48l2c6fihxiui3hzgehkdymxvoir8dqzaj08s
ESTA
17 Apr 24
.
At the meeting, Dr. Caroline Glicksman, the Medical Director and an Investigator in the Motiva US IDE Study, will present an update
5gddfd5vtskj69b94kla412h2by1ysv4y3dns2ps9
ESTA
1 Apr 24
.
Investigating Analyst Ratings: An Elaborate Study
In examining recent analyst actions, we gain insights into how
- Prev
- 1
- Next